Skyler B. Johnson, MD

Journal Article

1. Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR study. International journal of radiation oncology, biology, physics,
2. Fridman I, Smith C, Barrett A, Johnson S, Bhowmick A, Hayes S, Elston Lafata (2025). Navigating Disagreements on Health Information: How Patients With Cancer Perceive Health Care Providers' Approaches to Discussing Patient-Identified Information. JCO oncology practice, OP2400071.
3. Parker ND, Johnson SB, King AJ, Amin TB, Swire-Thompson B, Zhang Z, Bylund C (2025). Assessing Cancer Patients' Exposure to Treatment Misinformation. Journal of cancer education,
4. Huisman KM, Whitaker MK, Johnson SB, Walker G (2025). Paging Dr. Google: Characterizing Direct-to-Consumer Digital Advertisements From Oncology Treatment Centers. Cureus, 17(3), e80994.
5. Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clinical proteomics, 22(1), 13.
6. Turner CA, King AJ, Tovar I, Millar MM, Codden RR, Guo JW, Johnson S, Kirchhoff AC, Raber M, Sheng X, Kepka D, Warner E (2025). Evaluating the Feasibility of Web-Monitoring Methodology for Measuring Exposure to Online Cancer Misinformation. JMIR cancer, 11, e65887.
7. Fridman I, Johnson SB, Derry-Vick H (2025). When Limited Clinical Time With Patients Meets Unlimited Online Information. JMIR cancer, 11, e79031.
8. Howell JN, Wilkes J, Maughan NM, Patel RB, Barney B, Taunk NK, Escorcia FE, Johnson SB, Boothe (2025). Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade. International journal of radiation oncology, biology, physics,
9. Hutten RJ, Odei B, Johnson SB, Tward J (2024). Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers. JCO precision oncology, 8, e2300364.
10. Bylund CL, Taylor G, Vasquez TS, Alpert J, Johnson SB, Le T, Paige SR, Close J, Markham M (2024). Talking with clinicians about online cancer information: a survey of cancer patients and surrogate information seekers. Supportive care in cancer, 32(6), 362.
11. Mullis MD,Fisher CL,Johnson SB,Liu T,Amin TB,Rogers S,DeGruccio K,Bylund C (2024). Clinician-patient communication about cancer treatment misinformation: The Misinformation Response Model. PEC innovation, 5,
12. Roach E,Hutten R,Johnson S,Suneja G,Tward J,Petereit D,Gaffney (2024). The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy. Brachytherapy, 23(3), 360-367.
13. Swire-Thompson B, Kilgallen K, Dobbs M, Bodenger J, Wihbey J, Johnson (2024). Discrediting health disinformation sources: Advantages of highlighting low expertise. Journal of experimental psychology. General, 153(9), 2299-2313.
14. Bylund CL, Mullis MD, Alpert J, Markham MJ, Onega T, Fisher CL, Johnson S (2023). Clinician Communication With Patients About Cancer Misinformation: A Qualitative Study. JCO oncology practice, 19(3), OP2200526.
15. Johnson SB, King AJ, Warner EL, Aneja S, Kann BH, Bylund C (2023). Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI cancer spectrum, 7(2),
16. Johnson SB, Bylund C (2023). Identifying Cancer Treatment Misinformation and Strategies to Mitigate Its Effects With Improved Radiation Oncologist-Patient Communication. Practical radiation oncology,
17. Peterson J, Wilson TF, Watt MH, Gruhl J, Davis S, Olsen J, Parsons MW, Kann BH, Swire-Thompson B, Fagerlin A, Warner EL, King AJ, Chino F, Johnson S (2023). International medical tourism of US cancer patients for alternative cancer treatments: Financial, demographic, and clinical profiles of online crowdfunding campaigns. Cancer Med, 12(7), 8871-8879.
18. Hutten RJ,Weil CR,King AJ,Barney B,Bylund CL,Fagerlin A,Gaffney DK,Gill D,Scherer L,Suneja G,Tward JD,Warner EL,Werner TL,Whipple G,Evans J,Johnson S (2023). Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO oncology practice, 19(11), 1000-1008.
19. Johnson SB,King AJ,Warner EL,Aneja S,Kann BH,Bylund C (2023). Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI cancer spectrum, 7(2),
20. Fridman I,Johnson S,Elston Lafata (2023). Health Information and Misinformation: A Framework to Guide Research and Practice. JMIR medical education, 9,
21. Fridman I, Johnson S, Elston Lafata (2023). Health Information and Misinformation: A Framework to Guide Research and Practice. JMIR medical education, 9, e38687.
22. Parsons MW, Hutten RJ, Tward A, Khouri A, Peterson J, Morrell G, Lloyd S, Cannon DM, Johnson S (2022). The Effect of Maximum Tumor Diameter by MRI on Disease Control in Intermediate and High-risk Prostate Cancer Patients Treated With Brachytherapy Boost. Clinical genitourinary cancer, 20(1), e68-e74.
23. Hutten RJ, Nelson G, Sarkar V, Johnson SB, Tao R, Hitchcock Y, Chan J, Schroeder J, Kokeny (2022). Feasibility and clinical utility of a workflow interfacing radiation oncology lung stereotactic body radiotherapy treatment planning and diagnostic radiology. Practical radiation oncology, 12(6), e512-e516.
24. Seymour ZA, Daignault-Newton S, McLaughlin PW, Sandler H, Jackson W, Johnson SB, Miller D, Wei J, Sanda M, Hamstra D (2022). Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clinical and translational radiation oncology, 36, 56-62.
25. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, O'Neil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, 20(6), e453-e459.
26. Peterson J, Wilson T, Gruhl J, Davis S, Olsen J, Parsons M, Kann B, Fagerlin A, Watt M, Johnson (2022). Timing and Motivations for Alternative Cancer Therapy With Insights From a Crowdfunding Platform: Cross-sectional Mixed Methods Study. JMIR cancer, 8(2), e34183.
27. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of gastrointestinal cancer, 54(2), 492-500.
28. Seymour ZA,Daignault-Newton S,McLaughlin PW,Sandler H,Jackson W,Johnson SB,Miller D,Wei J,Sanda M,Hamstra D (2022). Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clinical and translational radiation oncology, 36, 56-62.
29. Peterson J,Wilson T,Gruhl J,Davis S,Olsen J,Parsons M,Kann B,Fagerlin A,Watt M,Johnson (2022). Timing and Motivations for Alternative Cancer Therapy with Insights from a Crowdfunding Platform: Cross-sectional Mixed Methods Study. JMIR cancer, 8(2),
30. Hutten R,Khouri A,Parsons M,Tward A,Wilson T,Peterson J,Morrell G,Dechet C,O'Neil B,Schmidt B,Kokeny K,Lloyd S,Cannon D,Tward J,Sanchez A,Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer,
31. Parsons M,Lloyd S,Johnson S,Scaife C,Soares H,Kim R,Kim R,Garrido-Laguna I,Tao (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of gastrointestinal cancer,
32. Weil CR,Parsons MJ,Hutten RJ,Lew FH,Johnson SB,Gaffney DK,Tao (2022). Patterns of care and outcomes of early stage I'II Hodgkin lymphoma treated with or without radiation therapy. Leukemia & lymphoma,
33. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & lymphoma, 64(2), 1-8.
34. Peterson JS, Plana D, Bitterman DS, Johnson SB, Aerts HJWL, Kann B (2022). Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials. Cancer medicine,
35. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R (2021). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol, 28(2), 663-675.
36. Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH (2021). Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer Prostatic Dis, 24(2), 414-422.
37. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson S (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical genitourinary cancer, 19(6), e360-e366.
38. Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, Spratt DE, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin (2021). Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. Journal of the National Cancer Institute, 114(7), 1036-1039.
39. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson S (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European urology open science, 23, 30-33.
40. Joseph Anthony Miccio, MD; Andrew Barsky, MD; Sarah Gao, MD; Vivek Verma, MD; Sonal S. Noticewala, MD, MAS; Vikram Jairam, MD; Skyler B. Johnson, MD; James B. Yu, MD, MHS; James E. Hansen, MD; Sanjay Aneja, MD; Yi An, MD; Roy H. Decker, MD, PhD; S. Bulent Omay, MD; Jing Li, MD, PhD; Goldie A. Kurtz, MD; Michelle Alonso-Basanta, MD, PhD; John Y.K. Lee, MD; Veronica Chiang, MD; Henry S. Park, MD, MPH (2020). Multi-Institutional Retrospective Review of Stereotactic Radiosurgery for Brain Metastasis in Patients with Small Cell Lung Cancer Without Prior Brain-Directed Radiotherapy. J Neurooncol.
41. Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL (2020). A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas, 49(7), 904-911.
42. Benjamin H. Kann, MD, Skyler B. Johnson, MD, Hugo J.W.L. Aerts, PhD, Raymond H. Mak, MD, Paul L. Nguyen, M (2020). Changes in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019. JAMA network open,
43. Miccio JA, Barsky A, Gao S, Verma V, Noticewala SS, Jairam V, Johnson SB, Yu JB, Hansen JE, Aneja S, An Y, Decker RH, Bulent Omay S, Li J, Kurtz GA, Alonso-Basanta M, Lee JYK, Chiang VL, Park H (2020). Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. Journal of radiosurgery and SBRT, 7(1), 19-27.
44. Miccio JA,Barsky A,Gao S,Verma V,Noticewala SS,Jairam V,Johnson SB,Yu JB,Hansen JE,Aneja S,An Y,Decker RH,Omay SB,Li J,Kurtz GA,Alonso-Basanta M,Lee JYK,Chiang VL,Park H (2020). Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small-cell lung cancer without prior brain-directed radiotherapy. Journal of radiosurgery and SBRT, 7(1), 19-27.
45. Loganadane G, Kann BH, Park HS, Johnson SB, Mehra S, Judson BL, Bhatia A, Belkacemi Y, Yarbrough WG, Burtness B, Husain ZA (2019). Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Res, 39(9), 4885-4890.
46. Johnson SB, Hung J, Kapadia N, Oh KS, Kim M, Hamstra DA (2019). Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. Pract Radiat Oncol, 9(1), e22-e28.
47. Kole AJ, Park HS, Johnson SB, Kelly JR, Moran MS, Patel AA (2019). Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep, 9(1), 9934.
48. Johnson SB, Gross CP, Yu J (2019). Methodology Flaws and Implications of a Complementary Medicine Study-In Reply. JAMA oncology, 5(3), 433.
49. Johnson S,Park H,Gross C,Yu (2019). Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. Obstetrical & gynecological survey, 74(4), 217-219.
50. Johnson SB, Park HS, Gross CP, Yu JB (2018). Use of Alternative Medicine for Cancer and Its Impact on Survival. J Natl Cancer Inst, 110(1).
51. Johnson SB, Yu JB (2018). Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Curr Oncol Rep, 20(9), 66.
52. Johnson SB, Decker RH (2018). Prophylactic Cranial Irradiation Versus Surveillance: Physician Bias and Patient-centered Decision-making. Clin Lung Cancer, 19(6), 464-466.
53. Johnson SB, Park HS, Gross CP, Yu J (2018). Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA oncology, 4(10), 1375-1381.
54. Johnson SB, Lester-Coll NH, Kelly JR, Kann BH, Yu JB, Nath SK (2017). Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer. Eur Urol, 72(5), 738-744.
55. Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D'Amico AV, Yu JB (2017). Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer.LID - 10.1093/jnci/djw281 [doi]. J Natl Cancer Inst, 109(6).
56. Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB (2017). Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. J Natl Compr Canc Netw, 15(12), 1494-1502.
57. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY (2016). Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol, 69(1), 50-7.
58. Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB (2016). Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol, 121(2), 294-298.
59. Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA (2016). MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia, 18(4), 213-22.
60. Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA (2015). Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol, 38(5), 465-71.
61. Jackson WC, Johnson SB, Feng FY, Hamstra DA (2015 Aug). Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol, 38(4), 367-72.
62. Hamstra DA, Johnson SB, Daignault S, Zikmund-Fisher BJ, Taylor JM, Larkin K, Wood A, Fagerlin A (2015 Jan). The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making, 35(1), 27-36.
63. Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA (2014). Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol, 110(2), 291-7.
64. Johnson SB, Zhou J, Jolly S, Guo B, Young L, Prisciandaro JI (2014 May-Jun). The dosimetric impact of single, dual, and triple tandem applicators in the treatment of intact uterine cancer. Brachytherapy, 13(3), 268-74.
65. Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA (2014). Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol, 9, 245.
66. Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY (2014). Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol, 4(2), 99-107.
67. Johnson S, Jackson W, Speers C, Feng F, Hamstra D (2014). A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol, 4(6), 422-9.
68. Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY (2013). Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer, 119(18), 3287-94.
69. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D (2013). The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 86(3), 554-61.
70. Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY (2013). Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 85(5), 1246-53.
71. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY (2013 Oct 1). Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys, 87(2), 275-81.
72. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY (2013 Jul 8). A prostate-specific antigen doubling time of 6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol, 8, 170.

Review

1. Swire-Thompson B,Johnson (2024). Cancer: A model topic for misinformation researchers. Current opinion in psychology, 56,
2. Ford KL,Orsso CE,Kiss N,Johnson SB,Purcell SA,Gagnon A,Laviano A,Prado C (2022). Dietary choices after a cancer diagnosis: A narrative review. Nutrition (Burbank, Los Angeles County, Calif.), 103-104, 111838.

Book Chapter

1. Johnson SB, Decker R (2017). Radiation Therapy. 157.
2. Johnson SB, Damast S, Young (2016). Cervical Cancer.

Case Report

1. Johnson SB, Prisciandaro JI, Zhou J, Hadley SW, Reynolds RK, Jolly S (2014). Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report. J Appl Clin Med Phys, 15(1), 4520.

Editorial

1. Peterson JS, Swire-Thompson B, Johnson SB (2020). What is the alternative? Responding strategically to cancer misinformation. Future Oncol, 16(25), 1883-1888.
2. Johnson SB, Decker RH (Accepted). Prophylactic Cranial Irradiation Versus Surveillance:: Physician Bias in Prophylactic Cranial Irradiation (PCI) Decision Making-Opportunity for a Patient Decision Aid. Clin Lung Cancer,

Letter

1. Hutten RJ,Weil CR,Tward JD,Lloyd S,Johnson S (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European urology open science, 23, 30-33.

News

• 5 Warning Signs of Prostate Cancer That Men Should Never Ignore
• Get the Best Treatment for Early-Stage Prostate Cancer at Huntsman Cancer Institute

Huntsman Cancer Institute News

• A Unique Bond Built by Trust
• Talks with Docs: Skyler Johnson, MD
• Delivering a More Just, Equitable, & Inclusive Workplace
• Consider the Source: Identifying Cancer Misinformation